Biohaven Ltd. (BHVN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Biohaven Ltd. (BHVN) Healthcare & Pipeline Overview

Biohaven Ltd. is a clinical-stage biopharmaceutical company specializing in neurological and immunoscience therapies, aiming to disrupt existing treatment paradigms. With a focus on innovative drug development and a pipeline targeting unmet needs, Biohaven operates in the competitive biotechnology sector, striving to bring novel solutions to market.

What Is the Investment Thesis for BHVN?

Biohaven Ltd. presents an investment opportunity centered on its pipeline of neurological and immunoscience therapies. The company's focus on addressing unmet needs in these areas positions it to potentially capture significant market share if its drug candidates prove successful in clinical trials and gain regulatory approval. Key value drivers include the advancement of its lead programs through clinical development, strategic partnerships, and potential acquisitions. Growth catalysts include upcoming clinical trial readouts, regulatory submissions, and potential commercialization of its products. Investors should monitor the progress of its key programs, such as those targeting migraine and Alzheimer's disease, as well as its ability to secure partnerships and funding to support its development efforts. Potential risks include clinical trial failures, regulatory setbacks, and competition from other companies in the space. The company's market capitalization of $1.93B reflects investor expectations for its pipeline and future growth potential.

Based on FMP financials and quantitative analysis

BHVN Key Highlights

Biohaven focuses on neurological and immunoscience diseases, areas with significant unmet medical needs.

• The company's pipeline includes both small molecule and biologic therapies, providing diverse treatment options.
• Biohaven's strategy involves internal R&D, strategic collaborations, and in-licensing to expand its portfolio.
• The company is headquartered in New Haven, Connecticut, a hub for biopharmaceutical innovation.
• Biohaven aims to transform treatment paradigms through innovative drug development and clinical execution.

Who Are BHVN's Competitors?

BHVN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BHVN's Key Strengths?

Focus on neurological and immunoscience diseases.

• Pipeline of innovative drug candidates.
• Experienced management team.
• Strong intellectual property position.

What Are BHVN's Weaknesses?

Clinical-stage company with no approved products.

• Reliance on clinical trial success.
• Limited financial resources.
• High R&D expenses.

What Could Drive BHVN Stock Higher?

Clinical trial readouts for key pipeline programs.

• Regulatory submissions for new therapies.
• Strategic partnerships and collaborations.
• Expansion of commercial operations.
• Advancement of research and development efforts.

What Are the Key Risks for BHVN?

Financial-distress signal — its Altman Z-Score of -9.56 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures.
• Regulatory setbacks.
• Competition from other companies.
• Patent challenges.
• High R&D expenses.

What Are the Growth Opportunities for BHVN?

• Expansion of Migraine Portfolio: Biohaven has the opportunity to expand its migraine portfolio by developing and commercializing new formulations and delivery methods for its existing migraine therapies. The global migraine market is projected to reach $3.5 billion by 2027, driven by the increasing prevalence of migraine and the demand for more effective treatments. By leveraging its existing expertise and infrastructure, Biohaven can capture a larger share of this growing market and establish itself as a leader in migraine therapy.
• Advancement of Alzheimer's Disease Program: Biohaven's Alzheimer's disease program represents a significant growth opportunity, given the high unmet need and large market size. The global Alzheimer's disease market is expected to reach $12.6 billion by 2028, driven by the aging population and the lack of effective treatments. By successfully developing and commercializing a disease-modifying therapy for Alzheimer's disease, Biohaven can address a major public health challenge and generate substantial revenue.
• Strategic Partnerships and Acquisitions: Biohaven can pursue strategic partnerships and acquisitions to expand its pipeline and capabilities. By collaborating with other biotechnology and pharmaceutical companies, Biohaven can gain access to new technologies, drug candidates, and markets. Acquisitions can also provide Biohaven with valuable assets and expertise, accelerating its growth and diversification. These partnerships are crucial for expanding into new therapeutic areas and strengthening its competitive position.
• Expansion into Immunoscience: Biohaven's expansion into immunoscience represents a significant growth opportunity, given the increasing prevalence of autoimmune and inflammatory diseases. By developing and commercializing innovative therapies for autoimmune and inflammatory diseases, Biohaven can diversify its revenue streams and address a major unmet need.
• Global Expansion: Biohaven has the opportunity to expand its geographic reach by commercializing its products in new markets. By establishing a presence in key international markets, such as Europe and Asia, Biohaven can tap into new sources of revenue and diversify its geographic risk. Global expansion requires careful planning and execution, but it can significantly enhance Biohaven's long-term growth prospects.

What Are BHVN's Competitive Advantages?

• Proprietary drug candidates.
• Strong intellectual property protection.
• Clinical expertise.
• Established relationships with key opinion leaders.

What Does BHVN Do?

Biohaven Ltd., headquartered in New Haven, Connecticut, is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for neurological and immunoscience diseases. The company was founded with the goal of addressing significant unmet needs in these therapeutic areas, aiming to improve patient outcomes and transform treatment paradigms. Biohaven's approach involves a combination of internal research and development efforts, strategic collaborations, and in-licensing of promising drug candidates. Biohaven's pipeline includes a range of product candidates targeting various neurological conditions, such as migraine, Alzheimer's disease, and other neurological disorders. The company's focus extends to immunoscience, with programs aimed at treating autoimmune and inflammatory diseases. Biohaven's strategy involves developing both small molecule and biologic therapies, leveraging different modalities to address the complexities of these diseases. The company operates primarily in the United States, with potential for global expansion as its pipeline progresses through clinical development and regulatory approval. Biohaven competes with other biotechnology and pharmaceutical companies in the neurological and immunoscience spaces, seeking to differentiate itself through innovative science, clinical execution, and strategic partnerships. Biohaven is committed to advancing its pipeline and delivering meaningful therapies to patients in need.

What Products and Services Does BHVN Offer?

• Develops therapies for neurological diseases.
• Focuses on immunoscience disease treatments.
• Conducts clinical trials to evaluate drug candidates.
• Seeks regulatory approval for new therapies.
• Commercializes approved therapies.
• Engages in research and development activities.
• Collaborates with other companies and institutions.

How Does BHVN Make Money?

• Develops and commercializes pharmaceutical products.
• Generates revenue through sales of approved therapies.
• Partners with other companies for research and development.
• Out-licenses its technologies and drug candidates.

What Industry Does BHVN Operate In?

Biohaven Ltd. operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for neurological and immunoscience therapies is substantial, driven by the increasing prevalence of these diseases and the need for more effective treatments. The biotechnology industry is experiencing growth, fueled by advances in genomics, proteomics, and other technologies that are accelerating drug discovery and development. Biohaven competes with other biotechnology and pharmaceutical companies, academic institutions, and research organizations in the race to develop and commercialize new therapies. Success in this industry requires scientific expertise, clinical execution, regulatory acumen, and access to capital.

Who Are BHVN's Key Customers?

• Patients with neurological diseases.
• Patients with immunoscience diseases.
• Healthcare providers.
• Hospitals and clinics.
• Pharmaceutical distributors.

Company Profile

Biohaven Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New Haven, US. The company is led by CEO Vladimir Coric. BHVN has traded publicly since 2022.

Key Financial Metrics

Its free cash flow yield is -50.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -39.6%, the inverse of the P/E and a quick read on earnings relative to price.

BHVN Valuation & Market Position

With a $1.93B market cap, Biohaven Ltd. sits in the small-cap segment of the market. Analyst price targets span from $11.00 to $30.00, with a consensus of $20.00. At the current price of $12.79, that implies approximately 56% upside potential. Relative to its peer group, BHVN's quantitative score of 21/100 is below the peer average of 87/100.

Quarterly Financial Performance: Biohaven Ltd.

Revenue for Biohaven Ltd. came in at $0 during Q2 FY2026. The company recorded a net loss of $137.3M, with diluted EPS of $-0.91. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, BHVN averaged $-1.16 in diluted EPS.

Biohaven Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.56 places it in the distress zone, a signal of elevated financial risk.

Biohaven Ltd. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 6.9% below estimates on average.

Over the past six months, Biohaven Ltd. insiders filed 9 SEC Form 4 transactions — 1 sales and 8 purchases. On net that is roughly 481K shares acquired (about $4.6M) — insiders putting money in tends to read as conviction.

BHVN Financials

BHVN Latest News

BHVN Analyst Consensus

BHVN MoonshotScore

Latest Biohaven Ltd. Analysis

BHVN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources